Y-mAbs Therapeutics, Inc.https://pcaobus.org/form-ap-filings/38541/38541Y-mAbs Therapeutics, Inc.385414/9/2019 8:05:30 AM2018a02fba29-9d68-4414-9d03-bb7d4c8c25b1238PricewaterhouseCoopers LLP720549Y-mAbs Therapeutics, Inc.1722964YMAB0023800242Frank Douglas Midolo00238002421081PricewaterhouseCoopers Statsautoriseret RevisionspartnerselskabTrue
Y-mAbs Therapeutics, Inc.https://pcaobus.org/form-ap-filings/29081/29081Y-mAbs Therapeutics, Inc.290818/31/2018 12:00:41 PM2017105db01c-4f6c-49a3-ab83-2a6cbf9d5fa7238PricewaterhouseCoopers LLP720549Y-mAbs Therapeutics, Inc.1722964YMAB0023800242Frank Douglas Midolo00238002421081PricewaterhouseCoopers Statsautoriseret RevisionspartnerselskabTrue
ACHILLION PHARMACEUTICALS INChttps://pcaobus.org/form-ap-filings/17837/17837ACHILLION PHARMACEUTICALS INC178373/8/2018 11:13:17 AM2017ea376d7c-a8bf-46af-b2ec-80317c0213ab238PricewaterhouseCoopers LLP106131ACHILLION PHARMACEUTICALS INC1070336ACHN0023800242Frank Douglas Midolo0023800242True
ACHILLION PHARMACEUTICALS INChttps://pcaobus.org/form-ap-filings/2836/2836ACHILLION PHARMACEUTICALS INC28363/16/2017 8:28:59 AM2016f2edf671-10b8-4c2c-8e16-b7f91bd50ce3238PricewaterhouseCoopers LLP106131ACHILLION PHARMACEUTICALS INC1070336ACHN0023800242Frank Douglas Midolo0023800242True